No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients
| Autor: | Laura C. Gittleman, Michael J. Silverberg, Joanna Ready, Mary Patricia Pauly, Jennifer O Lam, Scott Chamberland, Daniel G. Korn, Julia L. Marcus, Jamila H. Champsi, Jennifer B. Lai, Suk I. Seo, Leo B. Hurley, Charles P. Quesenberry, Varun Saxena, David J. Witt |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Ledipasvir medicine.medical_specialty Time Factors Cirrhosis Genotype Sofosbuvir Hepatitis C virus Black People Hepacivirus medicine.disease_cause Antiviral Agents California Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus Internal medicine medicine Humans 030212 general & internal medicine Aged Aged 80 and over Fluorenes Hepatology business.industry Gastroenterology Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Treatment Outcome chemistry Relative risk Benzimidazoles Female 030211 gastroenterology & hepatology Transient elastography business medicine.drug |
| Zdroj: | Clinical Gastroenterology and Hepatology. 16:927-935 |
| ISSN: | 1542-3565 |
| DOI: | 10.1016/j.cgh.2018.03.003 |
| Popis: | BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week treatment course for black patients, but studies have not compared the effectiveness of 8 vs 12 weeks in black patients who are otherwise eligible for an 8-week treatment regimen. METHODS: We conducted an observational study of Kaiser Permanente Northern California members with HCV genotype 1 infection who were eligible for 8 weeks of treatment with ledipasvir and sofosbuvir (treatment-naive, no cirrhosis, no HIV infection, level of HCV RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|